Not All Omega-3s Are the Same
“Fish oil” is really shorthand for two distinct fatty acids that happen to travel together: EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid). They’re often listed side by side on a supplement label as if they’re interchangeable, but they behave quite differently in the body, and understanding that difference is the key to understanding why fish oil matters for brain health specifically.
DHA builds the brain’s architecture. EPA calms the inflammation that wears it down. You need both, doing different jobs.
DHA is structural. It’s the single most abundant omega-3 in brain tissue, woven directly into the membranes of neurons, where it keeps those membranes flexible enough for cells to communicate efficiently. Roughly 40 percent of the polyunsaturated fat in your neuronal membranes is DHA it’s quite literally part of the architecture your brain is built from, and that architecture matters a great deal for memory, learning, and processing speed as we age.
EPA, by contrast, is more of a messenger than a building block. Its primary job is producing signaling molecules that calm inflammation throughout the body, including in the brain. Chronic low-grade inflammation is increasingly understood as one of the quiet engines behind cognitive decline, and EPA is one of the few nutrients with a clear, well-documented mechanism for turning that inflammation down.
What the Research Actually Shows
Here is where we want to be careful, because this is a topic that gets oversold constantly, and a memory care community has a responsibility to talk about it honestly rather than chase a headline.
The laboratory and mechanistic case for omega-3s in brain health is genuinely strong. Multiple research teams have found that DHA and EPA appear to reduce inflammation in the brain, help maintain the integrity of neuronal membranes, and may assist the brain in clearing beta-amyloid, the protein that clumps together to form the plaques associated with Alzheimer’s disease.
The picture in actual clinical trials with people, however, is more mixed than the lab science alone would suggest, and the honest answer is that timing and dose both seem to matter enormously. A 2025 randomized trial found that twelve months of DHA supplementation improved cognitive performance specifically in people who already had mild cognitive impairment, not healthy adults with no symptoms. A separate Japanese trial found that 1,200 milligrams of daily DHA over eighteen months helped preserve memory and slow shrinkage of the hippocampus, the brain’s memory center, again in an older, higher-risk population. Meanwhile, a 2025 review of eleven placebo-controlled trials in cognitively healthy older adults found no meaningful benefit at all from supplementation in that lower-risk group.
Put plainly: the evidence increasingly suggests omega-3s are most helpful as a protective measure once some cognitive risk or early decline is already present, not as a guarantee against ever developing dementia in someone with a perfectly healthy brain today. A 2025 network meta-analysis also found that higher, EPA-dominant doses, generally in the 1,500 to 2,000 milligram per day range and often paired with antioxidants, showed the most promising results for cognitive benefit in people already living with Alzheimer’s dementia.
Why This Matters More for People at Genetic Risk
One detail from recent research deserves special mention for families navigating a new diagnosis or a strong family history. People who carry the APOE4 gene variant, the most well-established genetic risk factor for Alzheimer’s, appear to respond differently to omega-3s than the general population, and a 2024 trial in APOE4 carriers found that high-dose supplementation helped preserve neuronal integrity and slowed the progression of certain brain changes visible on MRI. If dementia runs in your family, this is exactly the kind of conversation worth having with a physician, since the right approach may genuinely differ from generic advice.
The Simplest, Best-Supported Step: Eat the Fish
Long before fish oil supplements existed, researchers studying populations who simply ate fish regularly noticed something worth paying attention to: greater fish consumption among older adults has been associated with a 30 to 50 percent reduction in risk of developing dementia and Alzheimer’s disease in some studies. Whole fish brings EPA and DHA along with protein, vitamin D, and other nutrients that may work together in ways an isolated supplement capsule simply can’t replicate.
Fatty, cold-water fish are the richest natural sources: salmon, sardines, mackerel, and trout among them. For residents and families who prefer a supplement, look for a product that lists the actual milligrams of EPA and DHA, not just “fish oil” as a vague total, and talk to a physician before starting, particularly for anyone on blood thinners, since omega-3s can have a mild blood-thinning effect of their own.
Our Perspective at Everwood Reserve
We think about nutrition the same way we think about every other part of memory care: as one piece of a much larger picture, never a substitute for medical guidance, and never oversold as more certain than the science actually allows. Omega-3 fatty acids are one of the more promising, well-studied nutritional tools we have for supporting brain health as we age, particularly once some cognitive change has already begun. They are not a cure, and no responsible source will ever tell you otherwise.
What we can tell you, from years at the bedside, is that the small, consistent things like what’s on the plate, how well someone sleeps, how connected they feel to the people around them all add up in ways that matter. Fish oil is one small, well-evidenced piece of that larger picture, and we think families deserve to understand it clearly rather than have it marketed to them.
-Joseph Rasberry MPAS, PA-C
Director of Clinical Operations
Everwood Reserve
Sources
1. Kalamara TV, et al. “Omega-3 Fatty Acids in Alzheimer’s Disease Prevention Among Elderly Women.” Neurodegenerative Disease Management, Dec. 2025.
2. “Omega-3 Fatty Acids and Alzheimer’s Disease: Current Evidence and Emerging Insights.” PMC, National Institutes of Health, 2025.
3. “Exploring the Preventive Effects of Omega-3 Polyunsaturated Fatty Acids Supplementation on Global Cognition: A Systematic Review and Meta-Analysis.” Nutrients (MDPI), Aug. 2025.
4. “Omega-3 Polyunsaturated Fatty Acids and Cognitive Decline in Adults with Non-Dementia or Mild Cognitive Impairment: An Overview of Systematic Reviews.” Nutrients (MDPI), Sept. 2025.
5. “An Analysis of Omega-3 Clinical Trials and a Call for Personalized Supplementation for Dementia Prevention.” Expert Review of Neurotherapeutics, 2024.
6. “The Omega-3 Index in Alzheimer’s Disease: Ready for Prime Time?” PMC, National Institutes of Health.
7. McNamara, Robert, PhD. University of Cincinnati Lipidomics Research Program, cited in Pharmacy Times, “Ongoing Clinical Trial Compares Omega-3 Types for Dementia Risk Reduction.”
8. Superpower Health, “EPA vs. DHA: Do These Two Omega-3s Actually Do Different Things?” 2026.
